Company news

Beijing Foyou Pharma Co., Ltd. news in 2025

Beijing Foyou Pharma Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Announcement on Change of Investor Contact Number

December 26, 2025

Announcement on Completion of Industrial and Commercial Filing

December 18, 2025

Announcement on Approval Notice for Clinical Trials of Ketoprofen Gel Patch

November 27, 2025

Announcement on the Election of Employee Directors and the Adjustment of Audit Committee Members

November 14, 2025

Announcement on Obtainment of the Drug Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets (I)

November 11, 2025

Announcement on Proposed Selection in the 11th National Centralized Drug Procurement

October 29, 2025

Announcement on Convening the Q3 2025 Performance Briefing

October 28, 2025

Announcement on Obtaining Drug Registration Certificate for Dydrogesterone Tablets

October 21, 2025

Announcement on Obtaining Drug Registration Certificate for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II)

September 29, 2025

Announcement on Obtaining Drug Registration Certificate for Pioglitazone-Metformin Tablets (15 mg/850 mg)

September 16, 2025

Announcement on Obtaining Drug Registration Certificate for Arotinolol Hydrochloride Tablets

September 8, 2025

Announcement on Obtaining Drug Registration Certificate for Amlodipine Besilate and Benazepril Hydrochloride Capsules

September 4, 2025

Announcement on Obtaining Drug Registration Certificate for Levothyroxine Sodium Tablets

August 26, 2025

Announcement on Resolutions of the 2nd Meeting of the 3rd Board of Supervisors

August 18, 2025

Announcement on Convening the 2025 Semi-annual Performance Briefing

August 14, 2025

Announcement on Wholly-owned Subsidiary Changing Business License

August 13, 2025

Announcement on Abnormal Fluctuations in Stock Trading

August 4, 2025

Announcement on Obtaining Drug Registration Certificate for Lansoprazole Enteric Capsules

July 31, 2025

Announcement on Approval Notice of the Supplementary Application for Drugs Obtained by the Subsidiary

July 30, 2025

Announcement on Obtaining Drug Registration Certificate for Bifonazole Solution

July 29, 2025

Announcement on Obtaining Drug Registration Certificate for Amorolfine Hydrochloride Liniment

July 4, 2025

Announcement on Obtaining Drug Registration Certificate for Benidipine Hydrochloride Tablets

July 1, 2025

Announcement on Listing and Circulation of Restricted Shares in Initial Public Offering

June 24, 2025

Announcement on Obtaining Drug Registration Certificate for Acipimox Capsules

June 10, 2025

Announcement on Obtaining Notice of Approval for Drug Clinical Trials of Ketoprofen Patch

June 5, 2025

Announcement on Obtaining Notice of Approval for Drug Clinical Trials of Lidocaine Prilocaine Cutaneous Spray Solution

May 29, 2025

Announcement on the Completion of Term Change and Election of Board of Directors and Board of Supervisors and Appointment of Senior Management Members, Head of Audit Department and Securities Affairs Representative

May 28, 2025

Announcement on Resolution of the 1st Extraordinary General Meeting in 2025

May 27, 2025

Announcement on Resolutions of the 17th Meeting of the 2nd Board of Directors

April 29, 2025

Announcement on Resolutions of the 2024 Annual General Meeting

April 28, 2025

Announcement on Obtaining Drug Registration Certificate for Rosuvastatin Calcium and Ezetimibe Tablets (I)

April 25, 2025

Announcement on Convening the Q1 2025 Performance Briefing

April 24, 2025